Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03254927 · OUTCOME

Clinical Benefit Response (CBR)

A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma · Source last updated 2023-04-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
Every 8 weeks, starting with first dose until disease progression, assessed up to approximately 2 years

What was measured

The percentage of patients who achieve best response of confirmed CR or PR, or stable disease (SD) for at least 12 weeks

Groups in this outcome

CDX-3379 and Cetuximab

During the treatment phase of the study, eligible patients will receive assigned treatments in 3 week cycles until progression. CDX-3379 and cetuximab: Dose: 12 mg/kg CDX-3379 once every 3 weeks in combination with 400 mg/m2 cetuximab on the first day followed by weekly doses of 250 mg/m2 cetuximab.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
CDX-3379 and Cetuximab30

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
CDX-3379 and Cetuximab40Not reported22.759.4Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        22.7
        upper Limit
        59.4
        value
        40
denoms
  1. counts
    1. group Id
      OG000
      value
      30
    units
    Participants
description
The percentage of patients who achieve best response of confirmed CR or PR, or stable disease (SD) for at least 12 weeks
dispersion Type
95% Confidence Interval
groups
  1. description
    During the treatment phase of the study, eligible patients will receive assigned treatments in 3 week cycles until progression. CDX-3379 and cetuximab: Dose: 12 mg/kg CDX-3379 once every 3 weeks in combination with 400 mg/m2 cetuximab on the first day followed by weekly doses of 250 mg/m2 cetuximab.
    id
    OG000
    title
    CDX-3379 and Cetuximab
param Type
NUMBER
reporting Status
POSTED
time Frame
Every 8 weeks, starting with first dose until disease progression, assessed up to approximately 2 years
title
Clinical Benefit Response (CBR)
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice